NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BlackRock TCP Capital Corp. (NASDAQ: TCPC) between November 6, 2024, and January 23, 2026, inclusive (the “Class Period”), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased BlackRock TCP securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange ...

Key TakeawaysThe UAE Ministry of Defence intercepted 9 ballistic missiles, 6 cruise missiles, and 148 drones on Monday, following a massive retaliatory barrage from Iran that has killed three people in the Emirates.Kuwait sounded air raid sirens again as smoke was reported rising near the US Embassy in Kuwait City, following a strike that killed six US service members at a local port.Australia’s S&P/ASX 200 index fell 0.2% to 9,180.70 in early trade as investors fled to safe-haven assets amid fears of a wid ...

分组1 - Life360 reported quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share, but showing an increase from $0.1 per share a year ago, resulting in an earnings surprise of -3.03% [1] - The company posted revenues of $145.98 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.37%, and showing a year-over-year increase from $115.53 million [2] - Life360 has surpassed consensus revenue estimates four times over the last four quarters, indicating a positive trend in revenue performance [2] 分组2 - The stock has underperformed the market, losing about 17.9% since the beginning of the year compared to the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the coming quarter is $0.18 on $138 million in revenues, and for the current fiscal year, it is $1.33 on $649 million in revenues [7] - The Zacks Industry Rank for Security and Safety Services is currently in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

分组1 - Nuvation Bio Inc. reported a quarterly loss of $0.11 per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of $0.15 per share a year ago [1] - The company posted revenues of $41.87 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 52.63%, compared to revenues of $5.71 million in the same quarter last year [2] - Nuvation Bio has surpassed consensus revenue estimates four times over the last four quarters, although it has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed, losing about 34% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.05 on revenues of $48.34 million, and for the current fiscal year, it is -$0.33 on revenues of $197.35 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Nuvation Bio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]

分组1 - Dave Inc. reported quarterly earnings of $3.69 per share, exceeding the Zacks Consensus Estimate of $3.5 per share, and showing a significant increase from $2.04 per share a year ago, representing an earnings surprise of +5.35% [1] - The company posted revenues of $163.7 million for the quarter ended December 2025, which was slightly below the Zacks Consensus Estimate by 0.18%, but an increase from $100.9 million year-over-year [2] - Over the last four quarters, Dave Inc. has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 12.7% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $2.72 on revenues of $128.17 million, and for the current fiscal year, it is $14.07 on revenues of $657.03 million [7] 分组3 - The Zacks Industry Rank indicates that the Technology Services sector is currently in the bottom 32% of over 250 Zacks industries, which may impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The estimate revisions trend for Dave Inc. was favorable ahead of the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6]

分组1 - Surgery Partners reported quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.31 per share, and down from $0.44 per share a year ago, representing an earnings surprise of -61.29% [1] - The company posted revenues of $885 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.31%, compared to year-ago revenues of $864.4 million [2] - Over the last four quarters, Surgery Partners has surpassed consensus EPS estimates just once and topped consensus revenue estimates two times [2] 分组2 - The stock's immediate price movement will depend on management's commentary on the earnings call and the sustainability of earnings expectations [3][4] - The current consensus EPS estimate for the coming quarter is $0.03 on revenues of $830.52 million, and for the current fiscal year, it is $0.63 on revenues of $3.51 billion [7] - The Zacks Industry Rank indicates that the Medical Services sector is currently in the bottom 41% of over 250 Zacks industries, which may impact stock performance [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities between October 9, 2025, and December 11, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PomDoctor securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2]. - The lawsuit alleges that PomDoctor made false and misleading statements and failed to disclose critical information regarding a fraudulent stock promotion scheme and insider trading activities [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [3].

Core Insights - The podcast episode features a discussion on the Capital Group Dividend Value ETF (CGDV) and its investment strategy [1] Group 1 - The Capital Group Dividend Value ETF (CGDV) focuses on dividend-paying stocks, aiming to provide investors with income and capital appreciation [1] - The ETF is designed to appeal to investors seeking a balance between growth and income through dividends [1] - The discussion highlights the importance of dividend growth in the current market environment, emphasizing its role in total return [1]

Core Viewpoint - WildBrain Ltd. has successfully sold its 41% stake in Peanuts Holdings LLC to Sony for CA $630 million, enhancing its financial position and enabling future investments in growth initiatives [1][2]. Financial Performance - The company has repaid its entire outstanding balance on its Senior Secured Credit Facility, eliminating corporate term debt and achieving a cash surplus of over CA $40 million [2]. Strategic Initiatives - Proceeds from the sale will support investments in core growth initiatives, including the expansion of wholly owned franchises like Strawberry Shortcake and Teletubbies, and the growth of WildBrain CPLG, the global licensing agency [2][5]. - The company aims to enhance its premium digital content network and advertising footprint across platforms such as YouTube, FAST, and AVOD [5]. Brand Management - WildBrain has significantly increased the value of the Peanuts brand through its expertise in content production and licensing, and plans to apply similar strategies to its other franchises [2]. - The management of the Peanuts brand will continue under Peanuts Worldwide LLC, with Sony owning 80% and the Schulz family retaining a 20% stake [2]. Company Overview - WildBrain is a global leader in family entertainment, managing franchises like Strawberry Shortcake, Teletubbies, and Inspector Gadget, and producing content for major platforms such as Apple TV and Netflix [3].

Core Viewpoint - Pioneering Technology Corp. reported a significant decline in revenue and net income for the first quarter ended December 31, 2025, while the CEO expressed optimism about future growth through ongoing business development efforts [1][2]. Financial Performance - Revenue for Q1 2025 was $461,135, down from $713,485 in Q1 2024, representing a decrease of approximately 35.3% [1][3]. - Gross profit for Q1 2025 was $239,579, compared to $372,302 in Q1 2024, resulting in a gross margin of 48% versus 52% in the previous year [1][3]. - Total expenses for Q1 2025 were $378,428, a slight decrease of 2.9% from $389,979 in Q1 2024 [1][3]. - The net loss for the quarter was $166,779, compared to a loss of $26,215 in Q1 2024 [1][3]. - Adjusted EBITDA for Q1 2025 was a loss of $137,239, contrasting with a profit of $35,801 in Q1 2024 [1][3]. Company Overview - Pioneering Technology Corp. is based in Mississauga, Ontario, and is recognized as North America's leader in cooking fire prevention technologies [2]. - The company focuses on developing energy-smart solutions to mitigate the risks associated with cooking fires, which are the leading cause of household fires in North America [2][4]. - Pioneering's patented technologies, such as temperature limiting control (TLC), are installed in over 450,000 multi-residential housing units, effectively preventing cooking fires [2].